Evidence map›Paper›PMID 26138646›Full record

ArticleJournal of the American Academy of Dermatology2015

Sirolimus use and risk of cutaneous squamous cell carcinoma (SCC) in solid organ transplant recipients (SOTRs).

Maryam M Asgari, Sarah T Arron, E Margaret Warton, Charles P Quesenberry, Dana Weisshaar

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of the American Academy of Dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Guidelines of care for the management of cutaneous squamous cell carcinoma.Journal of the American Academy of Dermatology · 2018
    Guideline
  2. Article
  3. Review
  4. Immunomodulators for Non-Melanoma Skin Cancers: Updated Perspectives.Clinical, cosmetic and investigational dermatology · 2023
    Review
  5. Investigative Landscape in Advanced Non-Melanoma Skin Cancers.Current treatment options in oncology · 2021
    Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Maryam M AsgariDivision of Research, Kaiser Permanente Northern California, Oakland, California; Department of Dermatology, University of California at San Francisco, San Francisco, California. Electronic address: maryam.m.asgari@kp.org.
Sarah T ArronDepartment of Dermatology, University of California at San Francisco, San Francisco, California.
E Margaret WartonDivision of Research, Kaiser Permanente Northern California, Oakland, California.
Charles P QuesenberryDivision of Research, Kaiser Permanente Northern California, Oakland, California.
Dana WeisshaarDepartment of Heart Transplant, Kaiser Permanente Northern California, Santa Clara, California.
Kaiser Permanente · USUniversity of California, San Francisco · US

Funding

Genome-wide association study of cutaneous squamous cell carincomaR01CA166672 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI ASGARI, MARYAM MANDANA · 2013 to 2016
$1.3M
NCI NIH HHS R01 CA 166672
6 · The paper itself

Abstract

backgroundLittle is known about the use of sirolimus for primary prevention of cutaneous squamous cell carcinoma (SCC) among solid organ transplant recipients (SOTRs).

objectiveWe examined the association between sirolimus exposure and incident SCC risk among SOTRs within Kaiser Permanente Northern California.

methodsUsing a retrospective cohort of all Kaiser Permanente Northern California members given a diagnosis of SOTR from 2000 through 2010, we evaluated incident posttransplantation SCC risk in relation to sirolimus exposure. Sirolimus use was determined from electronic pharmacy records, and incident posttransplantation SCCs were identified from health plan electronic pathology records. We used extended Cox regression to examine the independent association between receipt of sirolimus and risk of SCC.

resultsAmong 3539 SOTRs, 488 were exposed to sirolimus and 47 developed an incident SCC. SCC risk was not associated with ever use of sirolimus (adjusted hazard ratio 1.18, 95% confidence interval 0.84-1.16) or cumulative duration of sirolimus exposure (adjusted hazard ratio 2.75, 95% confidence interval 0.84-9.04, comparing long-term users with nonusers). LIMITATIONS: No information was available for some known SCC risk factors, such as skin type and sun exposure.

conclusionsAmong a large cohort of SOTRs, sirolimus exposure was not associated with a reduction in incident posttransplantation SCC risk.

Indexed as

AdultAgedCarcinoma, Squamous CellCohort StudiesConfidence IntervalsFemaleFollow-Up StudiesHumansImmunosuppressive AgentsIncidenceMaleMiddle AgedOrgan TransplantationProportional Hazards ModelsReference ValuesRetrospective StudiesImmunosuppressive AgentsSirolimusimmunosuppressionnonmelanoma skin cancerpharmacoepidemiologysirolimussolid organ transplantationsquamous cell carcinoma

Identifiers

PMID26138646
OpenAlexW1949347130

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.